Introduction
While seizure prognosis of epilepsy is largely determined by etiology, clinical trials are usually directed at seizure type and not epilepsy syndrome or etiology [1] . This may be one of the relevant reasons for the lack of progress in reducing the percentage of drug-resistant epilepsy patients over the last decades despite an increasing number of anti-seizure drugs (ASD) [2, 3] . Perampanel (PER) is a first in class noncompetitive antagonist of the ionotropic AMPA receptor [4] . PER has been approved by the United States Food and Drug Administration as an adjunctive treatment for focal seizures with or without secondary generalization in epilepsy patients N 12 years and for tonic-clonic seizures in idiopathic generalized epilepsy (IGE) [5] [6] [7] [8] . There are few data on PERs efficacy in specific etiologies such as glioma-related epilepsies [9, 10] A PubMed search for perampanel and heterotopia resulted in 0 references found.
A dysfunction of neuronal migration can result in heterotopic gray matter, which can be located uni-or bilaterally in the periventricular zone as nodules and frequently causes drug=resistant epilepsy [11, 12] . PVNH occurs sporadically and in familial forms. It is more common in females as the most frequent genetic cause, with a filamin A mutation that is X-linked [13] .
Here, we describe a patient with PVNH-associated active and highly drug-resistant focal epilepsy, who achieved sustained seizure freedom E-mail address: rosenow@med.uni-frankfurt.de (F. Rosenow).
after PER was added, in order to generate interest in a potentially specific utility for PER in this condition.
Case report
A 71-year-old cognitively unimpaired man with highly drug-resistant symptomatic epilepsy caused by bilateral symmetric periventricular heterotopia was treated in our outpatient clinic since January 2016. He reported near daily focal onset seizures and rare focal to bilateral tonic-clonic seizures since the age of 21 years. He described the focal seizures as beginning with a visual aura followed by aphasia and focal impaired awareness seizure. The MRI showed bilateral symmetric periventricular nodular heterotopia (PVNH) and bilateral hippocampal atrophy more pronounced on the left (Fig. 1 ). Comorbidities included essential tremor, glaucoma, arterial hypertension, arteriosclerotic heart disease and a thyroid hypofunction. No family history of epilepsy or risk factors for epilepsy were present. ASDs taken in the past included primidone (750 mg/d), lacosamide (300 mg/d), levetiracetam (3000 mg/d), lamotrigine (350 mg/d), brivaracetam (200 mg/d) as well as carbamazepine, valproate, topiramate, pregabalin, oxcarbazepine (unknown daily doses) resulted in a reduction of the number of bilateral tonic-clonic seizures but not the focal seizures and were associated with a number of side effects. His current medication of 600 mg of lacosamide, 750 mg of primidone and 300 mg of pregabalin was tolerated but did not have a significant impact on seizure frequency.
In December 2017, he was admitted to our epilepsy monitoring unit for presurgical evaluation and medication adjustment. The interictal EEG showed sharp waves over the left hemisphere, most frequently with a maximum over F3 and rarely with a bifrontal distribution ( Fig. 2A) . We recorded two right versive seizures evolving into bilateral tonic-clonic seizures associated with severe cyanosis and postictal apnoea as well as three subclinical seizures which were associated with a left frontal ictal onset zone (maximum Fz/F3, Fig. 2B ). An additional invasive evaluation using stereo-EEG was offered and compassionate use intraventricular valproate application (NCT02899611) was considered but both declined by the patient.
Perampanel was added in 12/2017 to his ongoing medication with a target dose of 8 mg/d. The preexisting anti-seizure medication was not modified. In a last follow-up in 11/2018, he reported to have suffered from only one focal seizure since the dose of 8 mg/d was reached in January 2018 with a seizure freedom of ten months.
Discussion
Unexpectedly, this man with a severe, highly drug resistant chronic structural epilepsy associated by a bilateral symmetric PVNH with nearly daily seizures for the first time achieved complete seizure freedom for ten months when perampanel was added to his anti-seizure polytherapy.
Data from the literature report the existence of an alteration of alpha-CaMKII and the NMDA-receptor complex in the epileptogenic brain tissue of human PVNH, suggesting a role in the basic mechanism of hyperexcitability associated with this brain dysgenesis. Corresponding immunocytochemistry showed that NMDA receptor subunit expression was decreased rather than increased as compared to normal neurons, especially when nodules extend to the neocortex [14] . These findings were supported by later investigations indicating that expressed levels of specific NMDA receptor subunits are altered in both cerebral heterotopia and cortical dysplasia in humans. Interestingly, a selective increase in the NR2B subunit was present in cortical dysplasia while the expressed level of NR2A and NR2B subunits is significantly downregulated in the patients with heterotopia. It is crucial to note, however, that this cohort did not have symmetrical bilateral PVNH [15] . An animal model with methylazoxymethonal (MAM) treated rats with heterotopia suggests, that a reduction of NR2A/B subunits is only present on at the postsynaptic level and not caused by expression, but eventually through phosphorylation [16] . Moreover, intrinsic ictal discharges of focal cortical dysplasias are mediated by excitatory amino acid receptors, notably by NMDA [17] . While a reduction in NMDA-R subunits appears counterintuitive, when postulating high efficacy of an AMPA-R antagonist, these results could implicate glutamatergic transmission in the hyperexcitability of nodular heterotopia leading to seizures.
Conclusions
The dramatic effect observed might be explained by exspect, cumulative polytherapy of several ASDs or possibly by an etiology-specific efficacy of PER in our patient with PVNH. To assess if the latter was the case, further clinical studies including case series and monotherapy reports would help validate our initial findings.
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